FindTrial
Sign In

Evaluating a gene-based test to predict which liver cancer patients are suitable for a living donor liver transplant (EHOP)

Evaluation and assessment of a Gene Expression Signature to Prognosticate Hepatocellular Carcinoma Patients for Living Donor Liver Transplantation (LDLT) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/098227
Enrollment
1200
Registered
2025-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

Intervention1: Nil: Nil

Sponsors

OPHIOMICS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with HCC who underwent LDLT from January 2019 to December 2022 with minimum 3-year follow-up

Exclusion criteria

Exclusion criteria: Incomplete clinical data or absence of adequate tissue samples for molecular analysis

Design outcomes

Primary

MeasureTime frame
Evaluate the performance of HepatoPredict in prognosticating survival outcomes in HCC patients undergoing LDLTTimepoint: 6 month—

Secondary

MeasureTime frame
Assess Hepato predicts ability to predict recurrence risk post transplant & compare it with establish clinical criteriaTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr Peush Sahni

Max Super Specialty Hospital

peush.sahni@maxhealthcare.com9999646488

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026